Champions Oncology Inc (NASDAQ:CSBR) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price objective of $14.33 for the company and are predicting that the company will post $0.04 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Champions Oncology an industry rank of 79 out of 255 based on the ratings given to its competitors.
A number of equities research analysts recently issued reports on CSBR shares. Zacks Investment Research upgraded shares of Champions Oncology from a “hold” rating to a “strong-buy” rating and set a $12.00 price objective for the company in a report on Monday, September 17th. Craig Hallum started coverage on shares of Champions Oncology in a report on Tuesday, July 17th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Janney Montgomery Scott started coverage on shares of Champions Oncology in a report on Monday, July 9th. They issued a “buy” rating for the company.
In other Champions Oncology news, Director Joel Ackerman sold 22,535 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $17.02, for a total transaction of $383,545.70. Following the completion of the sale, the director now directly owns 1,021,731 shares in the company, valued at $17,389,861.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel Newman Mendelson sold 8,333 shares of the company’s stock in a transaction dated Thursday, September 20th. The shares were sold at an average price of $13.02, for a total transaction of $108,495.66. Following the sale, the director now owns 62,500 shares of the company’s stock, valued at $813,750. The disclosure for this sale can be found here. Corporate insiders own 44.30% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Champions Oncology during the second quarter valued at about $104,000. Bank of Montreal Can bought a new stake in Champions Oncology during the third quarter valued at about $250,000. Renaissance Technologies LLC boosted its holdings in Champions Oncology by 63.3% during the second quarter. Renaissance Technologies LLC now owns 100,600 shares of the biotechnology company’s stock valued at $638,000 after acquiring an additional 39,000 shares during the period. Essex Investment Management Co. LLC bought a new stake in Champions Oncology during the second quarter valued at about $646,000. Finally, Perkins Capital Management Inc. bought a new stake in Champions Oncology during the second quarter valued at about $653,000. Institutional investors own 38.52% of the company’s stock.
NASDAQ:CSBR traded down $0.40 during trading hours on Friday, reaching $11.94. The company’s stock had a trading volume of 243,500 shares, compared to its average volume of 109,736. The stock has a market capitalization of $195.04 million, a PE ratio of -85.29 and a beta of -0.18. Champions Oncology has a one year low of $3.05 and a one year high of $17.90. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23.
Champions Oncology (NASDAQ:CSBR) last issued its quarterly earnings data on Thursday, September 13th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.03. The firm had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $5.85 million. Champions Oncology had a negative net margin of 1.63% and a negative return on equity of 97.02%. On average, sell-side analysts forecast that Champions Oncology will post 0.17 earnings per share for the current fiscal year.
Champions Oncology Company Profile
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Read More: Investing strategies using the yield curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.